Electra Therapeutics targets $978M valuation in IPO
Drug developer Electra Therapeutics aims for a valuation of up to $977.6 million in its US initial public offering. The company is offering about 21.67 million shares to raise up to $346.7 million.
Xurve View
Insights:
Xurve View
Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in its United States IPO, seeking to raise as much as $346.7 million. The offering extends a biotech listings rebound during a slower-than-usual fall IPO window. Electra plans to offer about 21.67 million shares priced between $14 and $16 apiece.
